Detalhe da pesquisa
1.
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
Br J Dermatol
; 186(3): 496-507, 2022 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34726270
2.
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Br J Dermatol
; 182(6): e186-e209, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32476149
3.
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Br J Dermatol
; 182(5): 1120-1135, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31407311
4.
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
Br J Dermatol
; 183(1): 39-51, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31564057
5.
Conjunctivitis in dupilumab clinical trials.
Br J Dermatol
; 181(3): 459-473, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30851191
6.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
Br J Dermatol
; 178(5): 1083-1101, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29193016
7.
Response to R. Waldman et al.: 'Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?'
Br J Dermatol
; 182(5): 1310-1312, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31853960
8.
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.
Br J Dermatol
; 181(1): 196-197, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30719707
9.
Response to critical appraisal of LIBERTY AD CHRONOS.
Br J Dermatol
; 179(6): 1423, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30318720
10.
Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors.
Br J Dermatol
; 178(5): 1220-1221, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29336016
11.
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.
J Dermatolog Treat
; 33(1): 266-277, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32347763
12.
Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble.
J Appl Physiol (1985)
; 73(3): 941-5, 1992 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-1400060